<DOC>
	<DOCNO>NCT02487992</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy cytokine-induced killer cell ( CIK ) plus S-1 Bevacizumab v S-1 Bevacizumab Maintenance Treatment patient advance colorectal cancer .</brief_summary>
	<brief_title>The Study CIK Plus S-1 Bevacizumab Maintenance Treatment Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>1200 patient stage Ⅳ colorectal cancer , receive surgery chemotherapy , randomly divide group A（receive CIK plus S-1 Bevacizumab ) group B（just receive S-1 Bevacizumab ) , randomize ratio 1:1 . Patients group A receive 3 cycle CIK treatment ( every 1 year ) Apatinib ( continuous ) .Patients group B receive S-1 Bevacizumab ( continuous ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients accept curative operation 1870 year old Histologically confirm colorectal cancer stage Ⅳ Patients accept oral drug ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Hemoglobin＜8.0 g/dL , White blood cell ＜3 X 10^9/L ; Platelet count ＜75 X 10^9/L ; alanine aminotransferase , glutamicoxalacetic transaminase , blood urine nitrogen creatinine normal limit 3.0 time Known suspect allergy investigational agent agent give association trial Pregnant lactating patient Known history Human Immunodeficiency Virus ( HIV ) , Hepatitis C Virus ( HCV ) TreponemaPallidun ( TP ) infection Patients suffer serious autoimmune disease Patients use long time use immunosuppressant Patients active infection Patients suffer serious organ dysfunction Patients suffer cancer Other situation researcher consider unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>